Experimental Drug DH20931 Shows Promise Against Triple-Negative Breast Cancer Through Novel Lipid-Targeting Mechanism
Key Insights
University of Florida researchers developed DH20931, an experimental drug that kills triple-negative breast cancer (search) cells by overwhelming them with toxic ceramide lipids through CerS2 (search) enzyme targeting.
The compound significantly slowed tumor growth in mouse models without causing toxicity and enhanced chemotherapy effectiveness by reducing required doxorubicin doses fivefold.
DH20931 employs a dual-pathway mechanism, triggering both lipid accumulation and calcium flooding to disrupt mitochondria and induce cancer cell death.
University of Florida researchers have developed an experimental drug that targets triple-negative breast cancer (search) through a novel mechanism involving toxic lipid accumulation. The compound, designated DH20931, overwhelms cancer cells with fat-like molecules called ceramides (search), causing them to self-destruct when they cannot cope with the metabolic stress.
Triple-negative breast cancer (search) represents one of the most aggressive forms of the disease, lacking three common drug targets that make other breast cancers more treatable. The new approach offers a potential therapeutic avenue for this challenging cancer subtype.
Mechanism of Action
DH20931 targets the enzyme CerS2 (search) to dramatically increase ceramide production within cancer cells. Lead researcher Satya Narayan, Ph.D., a professor in the University of Florida's College of Medicine and member of the UF Health Cancer Institute (search), explains the drug's effects using an electrical analogy.
"When that surge goes into the cancer cells, they cannot handle the amount of power they are getting. The fuses burn out, the cell can't handle the surge and it dies," Narayan said. While healthy cells act like properly grounded electrical circuits, cancer cells resemble "a jumble of mismatched wires and bad fuses" that cannot withstand the lipid surge.
The compound employs a dual-pathway approach beyond lipid accumulation. DH20931 also triggers calcium flooding within cells, creating a second stress signal. Together, these effects disrupt mitochondria—the cell's energy-producing structures—ultimately leading to cell death.
"It does not just follow one pathway but it goes through multiple pathways. It's a two-hit hypothesis," Narayan explained. "These pathways are common in all breast cancer (search) types and other solid tumors, so we think this drug can be useful not only in triple-negative breast cancer (search) but potentially other cancers as well."
Preclinical Results
In studies using human-derived tumors implanted in mice, DH20931 significantly slowed tumor growth without causing noticeable weight loss or signs of toxicity in the animals. The drug demonstrated selectivity for cancer cells, with healthy cells showing lower sensitivity in laboratory tests.
The compound also enhanced the effectiveness of standard chemotherapy. When combined with doxorubicin, a commonly used chemotherapy drug, researchers achieved equivalent cancer-killing effects while reducing the required doxorubicin dose by approximately fivefold. This dose reduction could potentially minimize chemotherapy-related side effects in future clinical applications.
Laboratory experiments revealed that DH20931 showed activity against other breast cancer (search) subtypes beyond triple-negative disease, suggesting broader therapeutic potential.
Development and Future Directions
The compound was developed in the laboratory of Sukwong Hong, Ph.D., at the University of Florida. Hong, now a professor at the Gwangju Institute of Science and Technology in South Korea, created DH20931 as part of a broader drug discovery program testing multiple candidates for efficacy.
Narayan and his international collaborators published their results on human-derived tumors April 21 in Molecular Cancer Therapeutics and presented combination therapy findings at the annual meeting of the American Association for Cancer Research in San Diego.
While the early results show promise, additional preclinical and clinical trials will be necessary to determine the safety and effectiveness of DH20931 as a potential cancer treatment for humans. The researchers' findings provide a foundation for advancing this novel therapeutic approach toward clinical development.